US Food and Drug Administration approves Novo Nordisk’s weight management drug Wegovy

DENMARK – Novo Nordisk, a Danish drug company that focuses on lifestyle related diseases, has finally received the US Food & Drug Administration (USFDA) approval of its weight management drug, Wegovy. The drug Wegovy (brand name for once-weekly semaglutide 2.4 mg injection in the US), was developed to be an adjunct to diet and exercise for chronic weight management in obese adults. Wegovy will be the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist   therapy approved for weight management for people living with obesity across the world. Approval was…

Read More